FDA Determines Regulatory Review Period for KYNAMRO Patent Extension Application

Summary

The U.S. Food and Drug Administration (FDA) has determined the regulatory review period for KYNAMRO, a human drug product, and is publishing this notice as required by law. The FDA made this determination due to a submission to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for patent extension.